XNCR News and Press, Xencor Inc.

2024-07-10 14:06:41 ET Summary Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after o...

2024-07-05 16:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-13 15:02:59 ET More on Xencor Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial information for Xencor Read the full article on Seeking Alpha For further details see: Xencor to regain rights from J...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, which Xencor advanced through ...

2024-06-05 08:46:27 ET Read the full article on Seeking Alpha For further details see: Vir gains on early mid-stage data for hepatitis candidate

2024-06-04 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-25 06:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-09 17:49:08 ET More on Xencor Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript Xencor slips as Piper cuts citing patient death in cancer study Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial info...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlig...